



IN THE UNITED STATES PATENT AND TRADE MARK OFFICE

APPLICANT: Gao, D. et al.) ATTORNEY DOCKET NO.: C-31691 US
SERIAL NO.: 09/451,641) GROUP PART UNIT: 1615
FILED: November 30, 1999) EXAMINER: S. T. [illegible]
TITLE: CHECOXIB COMPOSITIONS
DATE: February 18, 2003

RECEIVED

FEB 28 2003

TECH CENTER 1600/291

CERTIFICATE OF MAILING

I hereby certify that this communication and its recited enclosures are being deposited with the United States Postal Service as First Class Mail in a package addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on Feb 18, 2003.

Signed: Bernadette Y. Harper
Bernadette Y. Harper

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement (IDS) is filed in accordance with the duty of disclosure under 37 C.F.R. § 1.56 and §§ 1.97-1.98, as supplemented by MPEP § 609. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This IDS supplements that submitted on March 4, 2000, October 17, 2001, April 26, 2002, and July 10, 2002, and is filed under the provisions of 37 C.F.R. § 1.97(c) accompanied by authorization to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025.

Respectfully submitted.

James C. Forbes

James C. Forbes
Agent for Applicant
Registration No. 39,457
Tel. (847) 581-6090

Address Correspondence to:
Pharmacia Corporation
Global Patent Department
P.O. Box 1027
St. Louis, MO 63006

Attachments:
Fee Transmittal Sheet
Form PTO-1449
Copies of art cited
Post Card

C-3169/1/US

09/451.641

Applicant

Gao, D. et al.

Filing Date

Group No.

November 30, 1999

1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

TECH CENTER 1600 2901

/S.T./	Desai et al. (1996). Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size. <i>Pharmaceutical Research</i> , Vol. 13, No. 12, pp. 1838-1845		
	Florence et al. (1995). Factors Affecting the Oral Uptake and Translocation of Polystyrene Nanoparticles: Histological and Analytical Evidence. <i>Journal of Drug Targeting</i> , Vol. 3, pp. 65-70		
	Gershnik et al. (1998). Interaction of a Self-Emulsifying Liquid Drug Delivery System with the Everted Rat Intestinal Mucosa as a Function of Droplet Size and Surface Charge. <i>Pharmaceutical Research</i> , Vol. 15, No. 6, pp. 863-869		
	Kakoulides et al. (1998). Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity in vitro degradation and preliminary ex vivo bioadhesion studies. <i>Journal of Controlled Release</i> , 54, pp. 95-109		
	Kawamori et al. (1998). Chemopreventive Activity of Celecoxib, a Specific Cyclooxygenase-2 Inhibitor against Colon Carcinogenesis. <i>Cancer Research</i> , 58, pp. 409-412		
	Kulvanich & Stewart. (1987). The effect of particle size and concentrating on the adhesive characteristics of a model drug carrier interactive system. <i>J. Pharm. Pharmacol.</i> 39, pp. 673-678		
	McClean et al. (1998). Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. <i>European Journal of Pharmaceutical Sciences</i> . (Website Version) Vol. 6, Issue 2, pp. 153-163.		
	Rodriguez et al. (1998). Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. <i>Journal of Controlled Release</i> , 55, pp. 67-77		
	Rubinstein. (1995). Approaches and Opportunities in Colon-Specific Drug Delivery. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 12(2&3), pp. 101-149		
	Smith et al. (1998). Pharmacological analysis of cyclooxygenase-1 in inflammation. <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 13313-13318.		
/S.T./	Tirosh & Rubinstein. (1998). Migration of Adhesive and Nonadhesive Particles in the Rat Intestine under Altered Mucus Secretion Conditions. <i>Journal of Pharmaceutical Sciences</i> , Vol. 87, No. 4, pp. 453-456		
Examiner	/Susan Tran/	Date Considered	05/25/2008
Examiner	Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		